the essential EHR system selection guide - free download

    insync healthcare solutions revenue cycle management services

      2 min read

      Old Drug, New Use: Ketamine Combats Major Depression Disorder

      Featured Image

      In treating mental health, providers often come across patients whose Selective Serotonin Reuptake Inhibitors (SSRI) have no effect on their outcomes. With more than 30% of patients being SSRI-resistant, these individuals pose a challenge for mental health professionals to adequately treat. To progress patients back into their normal daily lives, researchers have had to look to the past in order to move forward.

      How Does Ketamine Combat Depression?

      Initially approved for anesthesia and pain relief, ketamine has been studied by researchers for new uses ever since its discovery. Last year, ketamine was approved for patients with major depression who are treatment-resistant.

      A group of proteins called 4E-BPs, involved in memory formation, is the key to unlocking the antidepressant effect of ketamine on the brain, according to researchers from three Canadian universities. The discovery could lead to better and safer treatments for certain patients suffering from major depression. Unlike standard antidepressants, which can take several weeks to have an effect, ketamine works within hours. Until now, little was known about the molecular mechanism that triggers the antidepressant effect of ketamine on the brain.

      In the study published in Nature, researchers from McGill University, Université de Montréal and Carleton University investigated the effect of ketamine on behavior and neuronal activity in mice. Using genetic tools to remove proteins from specific brain cells, the team found that when 4E-BPs are absent in the brain, specifically in neurons, ketamine cannot produce its antidepressant effect. 4E-BPs act as a switch to turn on or off the process of protein synthesis - an essential component of memory formation.

      "This is yet another prime example of how basic research, in this case the control of protein synthesis, leads to major discoveries in understanding disease and the hope of curing it," says co-author Nahum Sonenberg, a professor at the Department of Biochemistry at McGill University.

      The researchers examined the role of 4E-BPs on ketamine's effect in two major types of neurons: excitatory neurons, which make up most of the neurons in certain parts of the brain, and inhibitory neurons, which control excitatory neurons and have important effects on behavior.

      "We were expecting that 4E-BPs would only be important in excitatory cells, but surprisingly, removing 4E-BPs from inhibitory cells was sufficient to block the effect of ketamine," says co-author Jean-Claude Lacaille, a professor at the Department of Neurosciences at Université de Montréal.

      Medicine is Not One Size Fits All

      The discovery and approval of ketamine for treatment-resistant patients was considered a major advance in modern psychiatry. Despite its promise, ketamine remains a less-than-perfect therapy because it can be addictive. The researchers hope that their findings will pave the way for better and safer antidepressant therapies for patients with major depressive disorders.

      "Too many decisions continue to be made by a trial-and-error approach that can prolong the suffering of patients and affect their quality of life," says co-author Aguilar-Valles, a former research associate at McGill University and now an assistant professor at Carleton University. "Our discovery has the potential to bring us closer to find a safer alternative to ketamine, and ultimately to a personalized medicine approach, where medical treatments are tailored to the individual characteristics of each patient."

      The study also involved a clinician-researcher, Dr. Gabriella Gobbi, from the Department of Psychiatry at McGill University, who works with individuals affected with depression and other psychiatric illnesses.

      As next steps, the researchers will examine whether males and females have different responses to ketamine. This could have important implications for treatment for people with depressive disorders, among which women are significantly overrepresented.

      Electronic Prescription Software Are Not Created Equally

      Controlled substances require specialized software for prescription delivery. For any practice dealing with the electronic prescription of controlled substances (EPCS), you may find yourself acting under the presumptive belief that you'll have EPCS included. But EPCS is not something that is rolled into a standard software agreement. Be sure to ask up front.

      If you're looking for a way to electronically prescribe medications as well as controlled substances, the InSync Healthcare Solutions' EPCS option will bring e-prescribe software as well as controlled substance prescription into one platform that's fully integrated with health and medical records, scheduling, telemedicine and billing. The InSync Healthcare Solutions EHR allows your entire practice to work within one HIPAA compliant system. 

      Get a 5-Minute Video Demonstration Now

      5-minute InSync Mental Health Software Snapshot Demo


      National Health Center Week | Patient Appreciation Day

      Behavioral health patients recognize their therapy providers as their advocates for a capable life. They see the results through the caring treatment...

      Read More

      Healthcare For The Homeless Day

      The number of homeless persons in the US is estimated at 552,830. Health care is a need encompassing all physical and behavioral conditions, spanning...

      Read More

      What is e Prescribing?

      Also known as eMAR - electronic medication administration record - and eRx, e-prescribing is defined as using an electronic device to write, modify,...

      Read More